Risk factors for irritable bowel syndrome in turkish population:: role of food allergy (vol 41, pg 380, 2007)

被引：0

作者：

Uz, E. ^{[1
]}

Tuerkay, C.

Aytac, S.

Bavbek, N.

机构：

[1] Fatih Univ Med Sch, Dept Internal Med, Ankara, Turkey

[2] Fatih Univ Med Sch, Dept Gastroenterol, Ankara, Turkey

[3] Guven Hosp, Dept Gastroenterol, Ankara, Turkey

来源：

JOURNAL OF CLINICAL GASTROENTEROLOGY | 2007年 / 41卷 / 08期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

收藏

页码：795 / 795

页数：1

相关论文

共 43 条

[41] RETRACTION: A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial (Retraction of Vol 15, Pg 1159, 2022)
El-Haggar, S. M.
Hegazy, S. K.
Abd-Elsalam, S. M.
Elkaeed, E. D.
Al-Karmalawy, A. A.
Bahaa, M. M.
JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 2381 - 2381
[42] Prevalence of metabolic syndrome and its risk factors in Canadian children and adolescents: Canadian Health Measures Survey Cycle 1 (2007-2009) and Cycle 2 (2009-2011) (vol 36, pg 32, 2016)
MacPherson, M.
de Groh, M.
Loukin, L.
Prud'homme, D.
Dubois, L.
HEALTH PROMOTION AND CHRONIC DISEASE PREVENTION IN CANADA-RESEARCH POLICY AND PRACTICE, 2016, 36 (04): : 87 - 87
[43] RETRACTED: A Potential Role of Ethosuximide and Pentoxifylline in Relieving Abdominal Pain in Irritable Bowel Syndrome Patients Treated with Mebeverine: A Randomized, Double-Blind, Placebo-Controlled Trial (Retracted article. See vol. 15, pg. 2381, 2022)
El-Haggar, Sahar M.
Hegazy, Sahar K.
Abd-Elsalam, Sherief M.
Elkaeed, Eslam B.
Al-Karmalawy, Ahmed A.
Bahaa, Mostafa M.
JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 1159 - 1172

← 1 2 3 4 5 →